Correlation Between Zentalis Pharmaceuticals and Genscript Biotech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Zentalis Pharmaceuticals and Genscript Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zentalis Pharmaceuticals and Genscript Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Zentalis Pharmaceuticals Llc and Genscript Biotech, you can compare the effects of market volatilities on Zentalis Pharmaceuticals and Genscript Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zentalis Pharmaceuticals with a short position of Genscript Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zentalis Pharmaceuticals and Genscript Biotech.

Diversification Opportunities for Zentalis Pharmaceuticals and Genscript Biotech

0.07
  Correlation Coefficient

Significant diversification

The 3 months correlation between Zentalis and Genscript is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding Zentalis Pharmaceuticals Llc and Genscript Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Genscript Biotech and Zentalis Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zentalis Pharmaceuticals Llc are associated (or correlated) with Genscript Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Genscript Biotech has no effect on the direction of Zentalis Pharmaceuticals i.e., Zentalis Pharmaceuticals and Genscript Biotech go up and down completely randomly.

Pair Corralation between Zentalis Pharmaceuticals and Genscript Biotech

Given the investment horizon of 90 days Zentalis Pharmaceuticals Llc is expected to under-perform the Genscript Biotech. In addition to that, Zentalis Pharmaceuticals is 1.44 times more volatile than Genscript Biotech. It trades about -0.05 of its total potential returns per unit of risk. Genscript Biotech is currently generating about -0.04 per unit of volatility. If you would invest  352.00  in Genscript Biotech on October 10, 2024 and sell it today you would lose (225.00) from holding Genscript Biotech or give up 63.92% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy99.6%
ValuesDaily Returns

Zentalis Pharmaceuticals Llc  vs.  Genscript Biotech

 Performance 
       Timeline  
Zentalis Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Zentalis Pharmaceuticals Llc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Zentalis Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in February 2025.
Genscript Biotech 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Genscript Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Zentalis Pharmaceuticals and Genscript Biotech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Zentalis Pharmaceuticals and Genscript Biotech

The main advantage of trading using opposite Zentalis Pharmaceuticals and Genscript Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zentalis Pharmaceuticals position performs unexpectedly, Genscript Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genscript Biotech will offset losses from the drop in Genscript Biotech's long position.
The idea behind Zentalis Pharmaceuticals Llc and Genscript Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk